[The value of pharmacogenetic tests in antidepressive medication therapy].
The pharmacokinetics and effect of antidepressants are influenced by genetic factors. Modern methods of genotyping allow fast and inexpensive identification of genetic variants and thus can be used in clinical diagnostics to improve the tolerance to drug therapy. Numerous studies have investigated the significance of genetic variants in drug-metabolizing enzymes, drug and natural substrate transporters, neurotransmitter receptors, and molecules involved in signal transduction. While the interindividual differences in oral clearance, half-life, and bioavailability caused by genetic variants in the cytochrome P450 liver enzymes can be overcome by individual adjustment of dosage according to certain genotypes, the effects of genetic variants in antidepressive target structures are more difficult to translate into clinical recommendations. This article gives an overview of the currently available literature and points to situations in which the determination of pharmacogenetic variants might change drug therapy or therapeutic strategies for the individual patient. Dose adjustments for common antidepressant drugs based upon differences in pharmacokinetic parameters caused by genetic variability will be given.
Kirchheiner
J
J
Institut für Klinische Pharmakologie, Universitätsmedizin Berlin. julia.kirchheiner@uk-koeln.de
Sasse
J
J
Roots
I
I
Brockmöller
J
J
Bauer
M
M
D000928:Antidepressive Agents / Q000008:administration & dosage*; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D020022:Genetic Predisposition to Disease / Q000235:genetics; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods* / Q000639:trends*; D010641:Phenotype
D000928:Antidepressive Agents